Targeting c-Met in melanoma

GATA6 Promotes Colon Cancer Cell Invasion by Regulating Urokinase Plasminogen Activator Gene Expression

(2015) Narasimhaswamy S Belaguli et al.   NEOPLASIA

Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032

(2015) Elisabetta Vergani et al.   NEOPLASIA

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

(2014) Terence O'Reilly et al.   Translational Oncology

Evidence for tankyrases as antineoplastic targets in lung cancer

(2013) Alexander M Busch et al.   BMC CANCER

Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides

(2013) Neelu Puri et al.   CANCER LETTERS

Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non-Small Cell Lung Cancer

(2013) I. Kawada et al.   CANCER RESEARCH

Vemurafenib in melanoma

(2013) Heather M Shaw et al.   Expert Review of Anticancer Therapy

Alternative Signaling Pathways as Potential Therapeutic Targets for Overcoming EGFR and c-Met Inhibitor Resistance in Non-Small Cell Lung Cancer

(2013) Jason T. Fong et al.   PLoS One

Targeting NRAS in Melanoma

(2012) Fergal C. Kelleher et al.   CANCER JOURNAL

Hepatocyte growth factor activates Wnt pathway by transcriptional activation of LEF1 to facilitate tumor invasion

(2012) Fang-I Huang et al.   CARCINOGENESIS

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Resistance patterns with tyrosine kinase inhibitors in melanoma

(2012) Reinhard Dummer et al.   CURRENT OPINION IN ONCOLOGY

Vemurafenib

(2012) Anant Sharma et al.   DRUGS

The mTOR Signalling Pathway in Human Cancer

(2012) Helena Pópulo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Expression of the c-Met Proteins in Malignant Skin Cancers

(2011) Yoon-Jin Lee et al.   Annals of Dermatology

Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors

(2011) J. Qi et al.   CANCER RESEARCH

Targeting BRAF in Advanced Melanoma: A First Step toward Manageable Disease

(2011) A. Vultur et al.   CLINICAL CANCER RESEARCH

mTOR signaling in disease

(2011) Eva Dazert et al.   CURRENT OPINION IN CELL BIOLOGY

Association of activated c-Met with NRAS-mutated human melanomas

(2011) Chandrani Chattopadhyay et al.   INTERNATIONAL JOURNAL OF CANCER

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Hepatocyte growth factor twenty years on: Much more than a growth factor

(2011) Takahiro Nakamura et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Discovery of a Novel B-Raf Fusion Protein Related to c-Met Drug Resistance

(2011) Roslyn Dillon et al.   JOURNAL OF PROTEOME RESEARCH

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

β-Catenin Signaling Increases during Melanoma Progression and Promotes Tumor Cell Survival and Chemoresistance

(2011) Tobias Sinnberg et al.   PLoS One

GATA6 Activates Wnt Signaling in Pancreatic Cancer by Negatively Regulating the Wnt Antagonist Dickkopf-1

(2011) Yi Zhong et al.   PLoS One

c-MET as a potential therapeutic target and biomarker in cancer

(2011) J. Rafael Sierra et al.   Therapeutic Advances in Medical Oncology

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer

(2010) K Schmid et al.   BRITISH JOURNAL OF CANCER

Expression of cell adhesion molecules in human melanoma cell lines and their role in cytotoxicity mediated by tumor-infiltrating lymphocytes

(2010) Franco Pandolfi et al.   CANCER

MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors

(2010) V. Cepero et al.   CANCER RESEARCH

MET Pathway as a Therapeutic Target

(2010) Eric S. Kim et al.   Journal of Thoracic Oncology

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

(2010) J Rafael Sierra et al.   Molecular Cancer

Convergence between Wnt-β-catenin and EGFR signaling in cancer

(2010) Tianhui Hu et al.   Molecular Cancer

The Combination of Multiple Receptor Tyrosine Kinase Inhibitor and Mammalian Target of Rapamycin Inhibitor Overcomes Erlotinib Resistance in Lung Cancer Cell Lines through c-Met Inhibition

(2010) I. Nakachi et al.   MOLECULAR CANCER RESEARCH

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

(2010) N. Munshi et al.   MOLECULAR CANCER THERAPEUTICS

mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics

(2010) H. Pópulo et al.   Pigment Cell & Melanoma Research

mTOR and cancer: many loops in one pathway

(2009) Alejo Efeyan et al.   CURRENT OPINION IN CELL BIOLOGY

Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases

(2009) Bryan T. MacDonald et al.   DEVELOPMENTAL CELL

Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling

(2009) Shih-Min A. Huang et al.   NATURE

GSK3: a multifaceted kinase in Wnt signaling

(2009) Dianqing Wu et al.   TRENDS IN BIOCHEMICAL SCIENCES

15-Lipoxygenase-1 in Colorectal Cancer: A Review

(2009) S. Bhattacharya et al.   TUMOR BIOLOGY

WNT5A Expression Increases during Melanoma Progression and Correlates with Outcome

(2008) P. D. Da Forno et al.   CLINICAL CANCER RESEARCH

SUMOylation target sites at the C terminus protect Axin from ubiquitination and confer protein stability

(2008) Min Jung Kim et al.   FASEB JOURNAL

Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6

(2008) Y Adachi et al.   ONCOGENE

mTOR Is Activated in the Majority of Malignant Melanomas

(2007) Magdalena Karbowniczek et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY